MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Slc2a13, a risk gene for Parkinson’s disease associated with Snca and Lrrk2

    JW. Li, GX. Zhang, T. Wang, ZC. Lin, N. Xiong (Wuhan, China)

    Objective: To exploit the potential function of the risk gene Slc2a13 in PD progression. Background: 越来越多的证据证实了总体遗传位点和候选基因对帕金森病的贡献,以及两个最确定的风险基因,即α-突触核蛋白(Snca)和富含亮氨酸的重复激酶2(Lrrk2)。Slc2a13 编码哺乳动物肌醇转运蛋白,被认为是一种群体依赖性风险基因。越来越多的证据支持这样一种观点,即 Slc2a13 活性的改变强调了 PD 的发展。剖析转运蛋白活性降低如何导致多巴胺能神经元变性和丧失,可能会进一步加深我们对功能的理解。 Method: A total of 338 cases…
  • 2024 International Congress

    Long-read sequencing to identify unrevealed second hit in autosomal recessive Parkinson’s disease

    K. Daida, H. Yoshino, K. Billingsley, L. Malik, B. Baker, R. Genner, K. Paquette, M. Ishiguro, M. Funayama, Y. Li, K. Nishioka, C. Blauwendraat, N. Hattori (Bethesda, USA)

    Objective: Identify unrevealed variants in PRKN and PINK1 genes from young onset Parkinson’s disease (YOPD) patients. Background: Long-read sequencing has identified pathogenic repeats and structural…
  • 2024 International Congress

    Assessing Genome-wide Genetic Risk for Parkinson’s Disease in European Sub-Populations Across the Global Parkinson’s Genetics Program and National Biobanks

    G. Lobal_parkinson'S_genetics_program (gp2) (Bethesda, USA)

    Objective: To assess genome-wide genetic risk for Parkinson’s disease (PD) within and across genetically determined European ancestries (European, Ashkenazi Jewish, and Finnish) from the Global…
  • 2024 International Congress

    Leveraging Large-Scale Proteomics to Identify Protein Quantitative Trait Loci and Causal Effects on Parkinson’s Disease

    M. Lai, B. Benitez (Boston, USA)

    Objective: Integrate proteomics from the cerebrospinal fluid (CSF) and urine from the Parkinson’s Progression Markers Initiative cohort to prioritize the risk variants associated with Parkinson’s…
  • 2024 International Congress

    Young onset Dystonia-Parkinsonism, Intellectual Disability & Mineral deposits in Basal ganglia – Think “RAB39B” mutation

    N. Barad (Ahmedabad, India)

    Objective: Please consider RAB39B gene when encountering a young onset dystonia Parkinson phenotype alongside non-progressive intellectual disability and brain mineral deposits. This consideration is crucial…
  • 2024 International Congress

    LRRK2 Gene Mutation in Parkinson’s Disease

    A. Abbes, M. Mhiri, R. Ben Dhia, N. Gouta, M. Frih Ayed (Monastir, Tunisia)

    Objective: We aim to describe the clinical characteristics of PD linked to an LRRK2 mutation. Background: One of the most common monogenic forms of Parkinson's…
  • 2024 International Congress

    Spectrum of Movement Disorders in Vitamin B12 Deficiency: A Case Series from India

    L. Sahoo, A. Mishra, D. Dash, M. Karan (Bhubaneswar, India)

    Objective: We present a case series of movement disorders associated with vitamin B12 deficiency Background: Vitamin B12 deficiency can cause multiple neuropsychiatric disorders like peripheral…
  • 2024 International Congress

    PMM2 mutation

    H. Teive, J. Duarte, LE. de Farias, S. Raskin, F. Tensini, D. Amarante (Curitiba, Brazil)

    Objective: describe glycosylation type 1A PMM2 mutation presented as motor development regression and cognitive impairment proving to be a disease that should’ve been detected precociously.…
  • 2024 International Congress

    Deep brain stimulation-evoked potentials as an avenue to optimize stimulation outcomes in Parkinson’s disease

    B. Bahners, L. Goede, G. Meyer, L. Poser, L. Hart, A. Kühn, A. Horn (Boston, USA)

    Objective: Use deep brain stimulation (DBS)-evoked potentials recorded using dry-EEG electrodes to estimate stimulation outcome. Background: Subthalamic DBS effectively alleviates motor symptoms in Parkinson’s disease.…
  • 2024 International Congress

    Levels of change in interleukin-6 levels according to clinical stages of Parkinson’s disease in patients with and without Covid-19

    R. Juraev, B. Muminov, R. Matmurodov (Tashkent, Uzbekistan)

    Objective: Comparison of serum IL-6 levels in clinical stages Parkinson's disease  patients with and without Сovid-19. Background: Elevated levels of the cytokine IL-6 may indicate…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley